Reflections on the neurotherapeutic effects of hyperbaric oxygen

Efrati, Shai; Ben‐Jacob, Eshel

doi:10.1586/14737175.2014.884928

Cited by 72 publications

(80 citation statements)

References 24 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to the best of our knowledge, the optimal timing of treatment for patients with brain injury remains unknown. Efrati and Ben-Jacob (23) suggested that HBO therapy may begin either at the degenerative or regenerative stages and is usually safe 1 month following acute injury. Subset analysis of isolated mild TBI demonstrated a trend toward harm from HBO at 2.4 ATA, suggesting that HBO at 2.4 ATA may actually have a negative impact on isolated mild TBI symptoms (81), however, the optimal effective doses of pressure and oxygen concentration in HBO therapy remain unclear, as does the optimal duration of treatment.…”

Section: Discussionmentioning

confidence: 99%

Effect of hyperbaric oxygenation therapy on post‑concussion syndrome (Review)

Dong

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The present review evaluated the effect of hyperbaric oxygenation (HBO) therapy on post-concussion syndrome (PCS). Searches for publications from the earliest date possible up until the first week of 2016 were conducted using the electronic databases Cochrane, EBSCOhost, Embase, Ovid MEDLINE, PubMed and Web of Science. Additional trials were identified through reference list scanning. Randomized controlled trials assessing the effectiveness of HBO therapy in PCS were selected and tested for eligibility for inclusion in the present review. Two independent reviewers conducted data extraction and the Cochrane Collaboration's recommended method was used to assess the risk of bias in each study included. Review Manager 5.3 software was used for data synthesis and analysis and the standardized mean difference (SMD) or mean difference (MD) was estimated with a fixed or random effects model using a 95% confidence interval (CI). A total of 127 articles were identified, 4 of which were eligible for final analysis. The meta-analysis identified no difference in the Rivermead Post-Concussion Symptoms Questionnaire (MD=1.23; 95% CI, −3.47-5.94; P>0.05; I2=35%) or Post-Traumatic Stress Disorder Checklist (PCL) scores (SMD=0.12; 95% CI, −0.31-0.54; P>0.05; I2=0%) scores between groups receiving different oxygen doses. The differences in PCL scores (SMD=−0.13, 95% CI, −0.80-0.53; P>0.05; I2=63%) and neurobehavioral symptoms (SMD=−1.00, 95% CI, −2.58-0.58; P>0.05; I2=92%) between the HBO and sham groups were not significant. The current study demonstrated that HBO therapy has no significant effect on PCS compared with the sham group. Therefore, it was determined that effective design and execution of a large clinical trial, which includes treatment, control and sham groups is required in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of hyperbaric oxygenation therapy on post‑concussion syndrome (Review)

Dong

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Relative improvements were previously observed following the therapeutic use of hyperbaric oxygen in some stroke patients who had focal neuronal damage and substantial reduction of ATP production [145] . This method can also be applied to FA patients with focal iron deposits and pathological symptoms but special safety procedures may be required because of possible exacerbation of the mitochondrial induced oxidative stress.…”

Section: Future Prospects In the Treatment Of Thalassaemia And Friedrmentioning

confidence: 78%

“…The therapeutic use of hyperbaric oxygen as a prophylactic measure in asymptomatic FA patients before the onset of mitochondrial focal iron load could also be considered for improvement of neuronal function [145] . Relative improvements were previously observed following the therapeutic use of hyperbaric oxygen in some stroke patients who had focal neuronal damage and substantial reduction of ATP production [145] .…”

Section: Future Prospects In the Treatment Of Thalassaemia And Friedrmentioning

confidence: 99%

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases

Kolnagou

Kontoghiorghe

Kontoghiorghes

2014

WJM

View full text Add to dashboard Cite

Author contributions: Kolnagou A reviewed the organisational health structure of thalassaemia and Friedreich ataxia in Cyprus; Kontoghiorghe CN contributed the literature background on recent developments on thalassaemia and Friedreich ataxia and critically reviewed the clinical and other aspects of the manuscript; Kontoghiorghes GJ designed, wrote and edited the manuscript including the mechanisms of iron chelation therapy and iron metabolism and toxicity. AbstractThalassaemia major (TM) and Friedreich's ataxia (FA) are autosomal recessive inherited diseases related to the proteins haemoglobin and frataxin respectively. In both diseases abnormalities in iron metabolism is the main cause of iron toxicity leading to increased morbidity and mortality. Major efforts are directed towards the prevention of these diseases and also in their treatment using iron chelation therapy. Both TM and FA are endemic in Cyprus, where the frequency per total population of asymptomatic heterozygote carriers and patients is the highest worldwide. Cyprus has been a pioneering nation in preventing and nearly eliminating the birth of TM and FA patients by introducing an organized health structure, including prenatal and antenatal diagnosis. Effective iron chelation therapy, improved diagnostic methods and transfusion techniques as well as supportive therapy from other clinical specializations have improved the survival and quality of life of TM patients.Despite the tiresome clinical management regimes many TM patients are successful in their professional lives, have families with children and some are now living well into their fifties. The introduction of deferiprone led to the elimination of cardiac failure induced by iron overload toxicity, which was the major cause of mortality in TM. Effective combinations of deferiprone with deferoxamine in TM patients caused the fall of body iron to normal physiological ranges. In FA different mechanisms of iron metabolism and toxicity apply to that of TM, which can be targeted with specific iron chelation protocols. Preliminary findings from the introduction of deferiprone in FA patients have increased the hopes for improved and effective therapy in this untreatable condition. New and personalised treatments are proposed in TM and FA. Overall, advances in treatments and in particular of chelation therapy using deferiprone are transforming TM and FA from fatal to chronic conditions. The paradigm of Cyprus in the prevention and treatment of TM can be used for application worldwide.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Thalassaemia; Friedreich ataxia; Prenatal diagnosis; Survival; Chelation therapy; Deferiprone; Deferoxamine; Cyprus Core tip: Thalassaemia major (TM) and Friedreich's ataxia (FA) are inherited diseases related to iron toxicity, with high morbidity and mortality rates. Cyprus has the highest frequency of TM and FA worldwide. Prenatal diagnosis and other health policies almost abolished the birth of TM and FA patients in Cyprus. Deferiprone has increa...

show abstract

“…The minimal pressure needed to gain such a feeling should be 1.3 ATA. However, compressed air at 1.3ATA (significant by means of CNS environment),, in addition to the pressure effect, increases the plasma oxygen tension by more than 50% which makes it a low dose treatment rather than sham/placebo intervention [134]. This limitation can be overcome by cross-over design with clear objective end points (such as brain imaging).…”

Section: Hyperbaric Oxygen Therapy (Hbot)mentioning

confidence: 99%

“…As explained in detail by [134], the diverse and powerful innate repair mechanisms activated by HBOT are associated both with the elevated level of dissolved oxygen and with the elevated pressure.…”

Section: Bubbles Recompression (Blast Injury) -Hbot Has Been Used Formentioning

confidence: 99%

Treatment of persistent post-concussion syndrome due to mild traumatic brain injury: current status and future directions

Hadanny

Efrati

2016

Expert Review of Neurotherapeutics

Self Cite

View full text Add to dashboard Cite

Persistent post-concussion syndrome caused by mild traumatic brain injury has become a major cause of morbidity and poor quality of life. Unlike the acute care of concussion, there is no consensus for treatment of chronic symptoms. Moreover, most of the pharmacologic and non-pharmacologic treatments have failed to demonstrate significant efficacy on both the clinical symptoms as well as the pathophysiologic cascade responsible for the permanent brain injury. This article reviews the pathophysiology of PCS, the diagnostic tools and criteria, the current available treatments including pharmacotherapy and different cognitive rehabilitation programs, and promising new treatment directions. A most promising new direction is the use of hyperbaric oxygen therapy, which targets the basic pathological processes responsible for post-concussion symptoms; it is discussed here in depth.

show abstract

Reflections on the neurotherapeutic effects of hyperbaric oxygen

Cited by 72 publications

References 24 publications

Effect of hyperbaric oxygenation therapy on post‑concussion syndrome (Review)

Effect of hyperbaric oxygenation therapy on post‑concussion syndrome (Review)

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases

Treatment of persistent post-concussion syndrome due to mild traumatic brain injury: current status and future directions

Contact Info

Product

Resources

About